XML 372 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Share-based Payments (Tables)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Share-based Payments [Abstract]    
Disclosure of Share-based Payment Expense Table
The following table provides the classification of the Group’s consolidated share-based payment expense as reflected in the Consolidated Statement of Income/(Loss):
For the years ending December 31,
2020
$000s
2019
$000s
2018
$000s
General and administrative7,650 10,677 5,293 
Research and development3,068 3,791 7,344 
Total10,718 14,468 12,637 
  
Disclosure of RSU activity
RSU activity for the years ended December 31, 2020, 2019 and 2018 is detailed as follows:
Number of Shares/UnitsWtd Avg Grant Date Fair Value (GBP)
Outstanding (Non-vested) at January 1, 20185,589,416 1.09 
RSUs Granted in Period2,860,778 1.54 
Vested(513,324)1.06 
Forfeited(1,338,087)1.06 
Outstanding (Non-vested) at December 31, 2018 and January 1, 20196,598,783 1.29 
RSUs Granted in Period1,775,569 2.95 
Vested(3,738,005)1.10 
Forfeited— — 
Outstanding (Non-vested) at December 31, 2019 and January 1, 20204,636,347 2.08 
RSUs Granted in Period1,759,011 1.80 
Vested(2,781,687)1.54 
Forfeited(191,089)2.37 
Outstanding (Non-vested) at December 31, 2020 3,422,582 2.46 
  
Disclosure of stock option activity
Stock option activity for the years ended December 31, 2020, 2019 and 2018 is detailed as follows:
Number of OptionsWtd Average Exercise Price (GBP)Wtd Average of
remaining contractual
term (in years)		Wtd Average Stock Price at Exercise (GBP)
Outstanding at January 1, 20182,343,085 1.22 
Granted2,796,820 1.57 
Exercised(64,171)1.20 1.56
Forfeited— — 
Options Exercisable at December 31, 2018 and January 1, 20191,195,929 1.26 7.92
Outstanding at at December 31, 2018 and January 1, 20195,075,734 1.40 8.78
Granted3,634,183 0.84 
Exercised(237,090)1.98 2.81
Forfeited— — 
Options Exercisable at December 31, 2019 and January 1, 20204,349,921 0.93 8.34
Outstanding at at December 31, 2019 and January 1, 20208,472,827 1.16 8.55
Granted4,076,982 3.14 
Exercised(514,410)1.52 2.88
Forfeited(1,119,313)1.88 
Options Exercisable at December 31, 20205,447,405 0.98 7.46
Outstanding at December 31, 202010,916,086 1.81 8.38
  
Disclosure of terms and conditions of share-based payment arrangement
The fair value of the stock options awarded by the Company was estimated at the grant date using the Black-Scholes option valuation model, considering the terms and conditions upon which options were granted, with the following weighted-average assumptions:
At December 31,
2020
2019
2018
Expected volatility41.25 %35.68 %44.18 %
Expected terms (in years)6.115.816.08
Risk-free interest rate0.53 %1.85 %2.79 %
Expected dividend yield— — — 
Grant date fair value$1.72 $2.23 $0.96 
Share price at grant date$4.30 $2.57 $2.05 
  
Disclosure of range of exercise prices of outstanding share options
For shares outstanding as of December 31, 2020, the range of exercise prices is detailed as follow:
Range of Exercise Prices (GBP)Options
Outstanding		Wtd
Average
Exercise
Price (GBP)		Wtd Average of
remaining contractual
term (in years)
0.01
2,122,965 — 8.76
1.00 to 2.00
4,703,639 1.47 6.99
2.00 to 3.00
1,539,482 2.51 9.45
3.00 to 4.00
2,550,000 3.51 9.97
Total10,916,086 1.81 8.38
  
Disclosure of Subsidiary Share-based Payments
Subsidiary Plans
Certain subsidiaries of the Group have adopted stock option plans. A summary of stock option activity by number of shares in these subsidiaries is presented in the following table:
Outstanding as of January 1, 2020
Granted During the YearExercised During the YearExpired During the YearForfeited During the Year
Outstanding as of December 31, 2020
Alivio3,698,244 189,924 — — — 3,888,168 
Entrega972,000 — — — (10,000)962,000 
Follica1,309,040 — — — — 1,309,040 
Sonde1,829,004 363,830 — — — 2,192,834 
Vedanta1,450,100 493,951 (813)— (201,350)1,741,888 
Outstanding as of January 1, 2019
Granted During the YearExercised During the YearExpired During the YearForfeited During the Year
Outstanding as of December 31, 2019
Gelesis3,681,732 — — (110,386)(3,571,346)¹— 
Alivio2,393,750 1,329,494 (3,125)— (21,875)3,698,244 
PureTech LYT2,180,000 — — — (2,180,000)²— 
Commense540,416 — — — (540,416)— 
Entrega914,000 58,000 — — — 972,000 
Follica1,229,452 79,588 — — — 1,309,040 
Karuna1,949,927 — — — (1,949,927)¹— 
Sonde22,500 1,806,504 — — — 1,829,004 
Vedanta1,373,750 154,193 — — (77,843)1,450,100 
1    These shares represent the options outstanding on the date of deconsolidation of Karuna and Gelesis.
2    These shares represent the options outstanding on the date of exchange to PureTech stock options.


Outstanding as of January 1, 2018
Granted During the YearExercised During the YearExpired During the YearForfeited During the Year
Outstanding as of December 31, 2018
Gelesis2,728,232 953,500 — — — 3,681,732 
Alivio2,393,750 — — — — 2,393,750 
Akili2,385,355 — — — (2,385,355)¹— 
PureTech LYT— 2,180,000 — — — 2,180,000 
Commense418,750 121,666 — — — 540,416 
Entrega867,750 60,000 — (3,750)(10,000)914,000 
Follica1,271,302 — — (41,850)— 1,229,452 
Karuna855,427 1,111,000 — (4,125)(12,375)1,949,927 
Knode32,500 — — (32,500)— — 
Sonde35,000 — — (6,250)(6,250)22,500 
Tal1,663,806 — — (30,250)(2,750)1,630,806 
The Sync Project1,080,000 — — — (1,080,000)— 
Vedanta1,194,014 278,786 — (24,800)(74,250)1,373,750 
1    These shares represent the options outstanding on the date of Akili’s deconsolidation.
  
Disclosure of Weighted Average Exercise Prices for Options Outstanding
The weighted-average exercise prices and remaining contractual life for the options outstanding as of December 31, 2020 were as follows:
Outstanding at December 31, 2020
Number of options
Weighted-average exercise price
$
Weighted-average contractual life outstanding
Alivio3,888,168 0.21 7.65
Entrega962,000 0.70 2.80
Follica1,309,040 0.89 6.29
Sonde2,192,834 0.19 8.76
Vedanta1,741,888 7.48 6.15
  
Disclosure of Weighted Average Exercise Prices for Options Granted
The weighted average exercise prices for the options granted for the years ended December 31, 2020, 2019 and 2018 were as follows:
For the years ended December 31,
2020
$
2019
$
2018
$
Alivio0.47 0.49 — 
PureTech LYT— — 0.03 
Commense— — 1.34 
Entrega— — 1.95 
Follica— 0.03 — 
Karuna— — 9.42 
Sonde0.18 0.20 — 
Vedanta19.59 19.13 14.66 
  
Disclosure of Weighted Average Exercise Prices for Options Forfeited
The weighted average exercise prices for options forfeited during the year ended December 31, 2020 were as follows:
Forfeited during the year ended December 31, 2020Number of options
Weighted-average exercise price
$
Vedanta201,350 16.03 
  
Disclosure of Weighted Average Exercise Prices for Options Exercisable
The weighted average exercise prices for options exercisable as of December 31, 2020 were as follows:
Exercisable at December 31,Number of Options
Weighted-average exercise price
$
Exercise Price Range
$
Alivio3,888,168 0.04
0.03-0.49
Entrega918,164 0.64
0.03-2.36
Follica1,273,326 0.89
0.03-1.40
Sonde774,2380.20
0.13-0.20
Vedanta1,119,28911.64
0.02-19.94
  
Significant Subsidiary Plan -Vedanta 2010 Plan - Range of assumptions of Fair Value of stock option grants   The fair value of the stock option grants has been estimated at the date of grant using the Black-Scholes option pricing model with the following range of assumptions:
Assumption/Input
2020
2019
2018
Expected award life (in years)
6.00-10.00
5.86-6.07
6.03-6.16
Expected award price volatility
89.24%-95.46%
89.24%-95.46%
91.60%-92.56%
Risk free interest rate
0.32%-0.87%
1.73%-1.88%
2.65%-2.78%
Expected dividend yield———
Grant date fair value
$13.09-$16.54
$14.12-$15.61
$11.21-$11.26
Share price at grant date
 $19.59
$18.71-$19.94
$14.66
Significant Subsidiary Plan Gelesis 2016 Plan - Range of assumptions of Fair Value of stock option grants
The fair value of the stock option grants has been estimated at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:
Assumption/Input
2020
2019
2018
Expected award life (in years)— 06.22
Expected award price volatility— %— %64.58 %
Risk free interest rate— %— %2.79 %
Expected dividend yield— — —
Grant date fair value$— $— $7.84 
Share price at grant date$— $— $12.82 
  
Significant Subsidiary Plan Karuna 2009 Plan - Range of assumptions of Fair Value of stock option grants
The fair value of the stock option grants has been estimated at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:
Assumption/Input
2020
2019
2018
Expected award life (in years)— 06.07
Expected award price volatility— %— %50.28 %
Risk free interest rate— %— %1.95 %
Expected dividend yield— — — 
Grant date fair value$— $— $3.51 
Share price at grant date$— $— $7.08